This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
The Zacks Analyst Blog Highlights: Moderna, Quanta Services, Avantor, ON Semiconductor and KLA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Quanta Services, Avantor, ON Semiconductor and KLA
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $440.72, marking a +1.54% move from the previous day.
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.
Top 5 High-Flying Stocks That Have Survived September Mayhem
by Nalak Das
We have narrowed down our search to five large-cap stocks that have gained nearly 5% or more than 5% month to date. These are: AVTR, PWR, ON, KLAC, and MRNA.
Fed's FOMC Meeting in Focus
by Zacks Equity Research
Fed's FOMC Meeting in Focus.
Housing Data Better than Expected on Growth in Northeast
by Mark Vickery
Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
Moderna (MRNA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $440.65, moving +1.42% from the previous trading session.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
Trade Desk, Okta, Microsoft and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Trade Desk, Okta, Microsoft and Moderna highlighted as Zacks Bull and Bear of the Day
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
by Zacks Equity Research
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
Green Across the Board at Closing Bell
by Mark Vickery
All four market indexes are off the recent highs we saw last Thursday, so even today's healthy trading environment wasn't enough.
5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now
by Zacks Equity Research
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.
aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923
by Zacks Equity Research
aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.
Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Novavax (NVAX) Stock Surges YTD as COVID Vaccine Advances Well
by Zacks Equity Research
Upon approval and successful commercialization, Novavax's (NVAX) COVID-19 vaccine should reap huge revenues. The company's other pipeline candidates also show promise.
Has Moderna (MRNA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M
by Zacks Equity Research
Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.
Will COVID-19 Vaccines for Children be Available by Year-End?
by Zacks Equity Research
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.